While the broader market has been all over the place over the past few months, one area that has performed significantly better than the S&P 500 is the biotech sector. Of course, while promising clinical trial results or regulatory approval of a treatment can serve as the catalyst that sends shares of biotech companies soaring, it’s critical to separate the biotechs poised for massive growth from those destined for failure. Today’s article highlights three biotech stocks that are all Buy-rated, trading under $4 a share, and have at least 50% upside potential. For more, CLICK HERE.
3 Under-$4 Biotech Stocks With Massive Growth Prospects
Tags:Biotech InvestmentsBiotech SectorBiotech StocksInvestInvestingInvestmentS&P 500Stock Growthstock marketUpside Potential